4.4 Article

Associations between haemoglobin A1cand mortality rate in the KORA S4 and the Heinz Nixdorf Recall population-based cohort studies

Journal

DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 37, Issue 2, Pages -

Publisher

WILEY
DOI: 10.1002/dmrr.3369

Keywords

epidemiology; HbA(1c); mortality; pre-diabetes; type-2 diabetes

Funding

  1. Deutsche Forschungsgemeinschaft [RA 459/3-1]
  2. Helmholtz Zentrum Munchen-German Research Center for Environmental Health
  3. German Federal Ministry of Education and Research [01ER1704]
  4. Volkswagen Foundation
  5. Siemens HealthCare Diagnostics
  6. Sarstedt AGCo
  7. Roche Diagnostics
  8. ResMed Foundation
  9. Philips
  10. Merck KG
  11. Janssen Pharmaceuticals
  12. Imatron/GE-Imatron
  13. Celgene GmbH Munchen
  14. Dr. WernerJackstadt Stiftung
  15. Protein Research Unit within Europe
  16. Kulturstiftung Essen
  17. German Competence Network Heart Failure
  18. European Union
  19. University Duisburg-Essen
  20. University Hospital Essen
  21. Competence Network for HIV/AIDS
  22. German Social Accident Insurance
  23. Else Kroner-Fresenius-Stiftung
  24. Ministry of Innovation, Science, Research and Technology, North Rhine-Westphalia
  25. German Ministry of Education and Science
  26. German Research Council
  27. Heinz Nixdorf Foundation

Ask authors/readers for more resources

In individuals with HbA(1c) levels below the diabetes threshold, there is no significant association between HbA(1c) levels of 39 to 41 mmol/mol (5.7%-5.9%) and 42 to 46 mmol/mol (6.0%-6.4%) and overall mortality. The mortality risks for newly detected diabetes (HbA(1c) >= 6.5%) and previously known diabetes vary with the length of follow-up, with weaker associations observed after 4 and 8 years, but stronger associations after 12 years.
Background There is limited knowledge about mortality risk in persons with increased haemoglobin A(1c)(HbA(1c)) levels below the diabetes threshold. Moreover, little is known about how associations between increased HbA(1c)and mortality depend on the length of follow-up. Therefore, we studied associations between HbA(1c)and mortality over long-term follow-up in persons with and without known diabetes. Methods We used data from two German population-based cohort studies: KORA S4 Study (Southern Germany, n = 1458, baseline visits in 1999 to 2001, baseline age 55 to 74 years, mortality follow-up 16.8 years) and Heinz Nixdorf Recall (HNR) Study (Ruhr area, n = 4613, baseline visits in 2000 to 2003, baseline age 45 to 75 years, mortality follow-up 17.8 years). Adjusted log-linear models were fitted to estimate relative risks (RRs) with 95% confidence intervals (CI). Results In both cohorts, participants with HbA(1c)39 to 41 mmol/mol (5.7%-5.9%) and HbA(1c)42 to 46 mmol/mol (6.0% to 6.4%) did not have a larger overall mortality risk than participants with HbA(1c) < 39 mmol/mol (5.7%): the corresponding adjusted RRs were 1.00 (95% CI: 0.83-1.21) and 1.01 (0.80-1.27) in KORA and 0.99 (0.82-1.21) and 0.83 (0.65-1.07) in the HNR Study. For the pooled cohorts, the RR for HbA(1c)39 to 46 mmol/mol (5.7%-6.4%) was 0.96 (0.85-1.07). Associations between newly detected diabetes (HbA(1c) >= 6.5%) and mortality were weak after 4 and 8 years of follow-up, but were stronger after 12 years of follow-up, whereas associations between previously known diabetes (baseline) and mortality decreased. Conclusions HbA(1c)-defined pre-diabetes is not associated with overall mortality. For newly detected and previously known diabetes, mortality risks vary with length of follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available